The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
|Videos|April 18, 2018
Inhibit CXCR4 to Treat CRC and Pancreatic Cancer
Author(s)Douglas T. Fearon, MD
In this video, Dr. Douglas Fearon outlines ways that inhibiting CXCR4 may provoke an immune response to treat pancreatic and colorectal cancer.
Advertisement
In this video, Dr. Douglas Fearon outlines ways that inhibiting CXCR4 may provoke an immune response to treat pancreatic and colorectal cancer.
Advertisement
Related to this article
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.
Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.
Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Building out a Radiopharmaceuticals Program in Oncology Care
3
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
4
Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression
5